Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
21
2024
FDA Issues Final Rule and Guidance on Direct-To-Consumer Prescription Drug Advertisements Sheppard, Mullin, Richter & Hampton LLP
Jun
18
2020
President Of Medical Technology Company Charged For Promoting Fake COVID-19 Treatment Sheppard, Mullin, Richter & Hampton LLP
Mar
9
2024
Oregon Prescription Drug Price Transparency Act in Limbo Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2017
Foreign Investment Under Trump Administration Sheppard, Mullin, Richter & Hampton LLP
Jan
11
2021
Medi-Cal Rx: California to Transition Medi-Cal Pharmacy Benefits to Fee-For-Service Sheppard, Mullin, Richter & Hampton LLP
Feb
18
2021
Recent FTC Settlement Serves as Reminder For Digital Health Developers Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2013
The Food and Drug Administration (FDA) Releases Long-Awaited Final Guidance on Mobile Medical Applications Sheppard, Mullin, Richter & Hampton LLP
Feb
17
2022
FDA Boosts Protein Preemption Defense Sheppard, Mullin, Richter & Hampton LLP
Jun
3
2014
Northern District of California Courts Still Searching for Sweet Spot in “Evaporated Cane Juice” Cases: Confusion Over Applicability of Primary Jurisdiction to ECJ Claims Continues Sheppard, Mullin, Richter & Hampton LLP
Jun
29
2022
California District Court Finds that EKRA Applies to Compensation Methodologies for Labs’ Employed Marketers Who Market to Physicians Sheppard, Mullin, Richter & Hampton LLP
Jul
6
2022
California Governor Signs into Law Cannabis Tax Relief Bill Sheppard, Mullin, Richter & Hampton LLP
Apr
17
2019
New York City Council Passes Legislation Banning Marijuana Testing of Job Applicants Sheppard, Mullin, Richter & Hampton LLP
Apr
22
2019
FDA Issues Warning Letter to Lab Marketing Three Laboratory-Developed Tests Sheppard, Mullin, Richter & Hampton LLP
Nov
4
2014
Mobile Health Apps are in a Boom Phase – Why is it so Hard for Pharmaceutical Companies to Find Users? Sheppard, Mullin, Richter & Hampton LLP
Oct
27
2022
FDA Proposes Updated Rule for “Healthy” Foods Sheppard, Mullin, Richter & Hampton LLP
Jul
29
2019
Delaware Supreme Court Allows Caremark Claim to Proceed Against Directors of Ice Cream Manufacturer Following Listeria Outbreak Sheppard, Mullin, Richter & Hampton LLP
Apr
21
2020
Telehealth and Online Prescribing: COVID-19 Triggers Changes to the Prescriber/Patient/Pharmacist Relationship Sheppard, Mullin, Richter & Hampton LLP
Oct
14
2016
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2020
President Trump’s Executive Order Mandating the Purchase of U.S. Drugs Evokes Criticism Sheppard, Mullin, Richter & Hampton LLP
Apr
3
2024
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA Sheppard, Mullin, Richter & Hampton LLP
Oct
2
2020
FDA’s Proposed Rule on “Intended Use” Confirms Agency Will Rely on “Any Relevant Source” of Evidence Sheppard, Mullin, Richter & Hampton LLP
May
7
2024
Cannabis Operator Challenges California State Statute and Regulations Requiring Labor Peace Agreements Sheppard, Mullin, Richter & Hampton LLP
Dec
4
2020
Cannabis Gets Go-Ahead from House, But Still Faces Hurdles Before Federal Legalization Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2010
The FDA Transparency Initiative: Another One Way Street? Sheppard, Mullin, Richter & Hampton LLP
Mar
13
2018
Under the Radar Changes to Proposition 65 – OEHHA Issues New “Guidance” For Web Purchases (Is it an Illegal “Underground Regulation”?) Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2021
Are Flavor Cases Fizzling? Two More Courts Grant Motions to Dismiss Sheppard, Mullin, Richter & Hampton LLP
Nov
18
2013
No Avoiding BPCIA (Biologics Price Competition and Innovation Act) For Biosimilars: No Patent Declaratory Judgment Action Before Biosimilars Application Is Filed Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins